WASHINGTON — The Biotechnology Industry Organization and the Delaware BioScience Association last week commended the Delaware State Senate for passing legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
The Delaware State Senate passed Senate Substitute 1 for Senate Bill 118.
“Senate Bill 118 enjoys the support of a broad coalition of biologic and biosimilar manufacturers, along with industry, physician and patient groups,” stated Jim Greenwood, BIO’s president and CEO. “This bill includes transparent communication on all biologic medicines dispensed in order to maintain a consistent and complete medical record. This legislation represents a significant step forward, ensures transparency and communication between patients and their treatment teams and is fully consistent with the BIO principles.”
The FDA is currently developing a pathway for the development and approval of safe and effective interchangeable biologic products in the United States.